Helmut Zepf Medizintechnik GmbH – Trademark Portfolio

Entity Type: 03

Helmut Zepf Medizintechnik GmbH holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 6 filings in this category. Currently, 2 trademarks are registered and 3 are pending. Notable registered marks include Z and XCISION. The owner is based in Seitingen-Oberflacht.

Obere Hauptstr. 16-22

Seitingen-Oberflacht 78606 , DE

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

NANOPAL
NANOPAL
Pending 2017
BENEX
BENEX
Pending 2017
Z
Z
Registered 2016
XCISION
XCISION
Registered 2015
XCISION
XCISION
Cancelled 2009

Trademark Classifications

Helmut Zepf Medizintechnik GmbH's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (6 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Helmut Zepf Medizintechnik GmbH have?

Helmut Zepf Medizintechnik GmbH has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 3 pending, 1 cancelled.

What trademark classes does Helmut Zepf Medizintechnik GmbH file in?

Helmut Zepf Medizintechnik GmbH files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Helmut Zepf Medizintechnik GmbH's most well-known trademarks?

Helmut Zepf Medizintechnik GmbH's registered trademark portfolio includes well-known marks such as Z and XCISION. These are among 2 currently registered trademarks in the portfolio.

What is Helmut Zepf Medizintechnik GmbH's trademark registration success rate?

Helmut Zepf Medizintechnik GmbH has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 3 applications are pending review.